Harrow (NASDAQ:HROW) Now Covered by HC Wainwright

HC Wainwright assumed coverage on shares of Harrow (NASDAQ:HROW) in a research note issued to investors on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $57.00 target price on the stock.

Separately, B. Riley reduced their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th.

Harrow Price Performance

HROW opened at $31.04 on Thursday. The business has a 50 day moving average of $35.22 and a 200-day moving average of $39.64. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow has a 1-year low of $9.30 and a 1-year high of $59.23.

Hedge Funds Weigh In On Harrow

A number of hedge funds and other institutional investors have recently made changes to their positions in HROW. JPMorgan Chase & Co. increased its stake in Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after acquiring an additional 194,480 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of Harrow in the 3rd quarter worth approximately $1,267,000. Penserra Capital Management LLC bought a new position in shares of Harrow during the 3rd quarter worth approximately $1,986,000. SG Americas Securities LLC acquired a new stake in Harrow in the 3rd quarter valued at $534,000. Finally, Semanteon Capital Management LP bought a new stake in Harrow in the third quarter valued at $686,000. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.